PMID- 11122544
OWN - NLM
STAT- MEDLINE
DCOM- 20010322
LR  - 20191104
IS  - 0929-5305 (Print)
IS  - 0929-5305 (Linking)
VI  - 10
IP  - 3
DP  - 2000 Dec
TI  - The TETAMI trial: the safety and efficacy of subcutaneous enoxaparin versus 
      intravenous unfractionated heparin and of tirofiban versus placebo in the 
      treatment of acute myocardial infarction for patients not thrombolyzed: methods 
      and design.
PG  - 241-6
AB  - Patients with acute myocardial infarction (AMI) who do not receive early 
      reperfusion therapy are at high risk of reinfarction or death, and the efficacy 
      and safety of antithrombotic therapy in this group of patients has not been 
      evaluated. Enoxaparin is a low-molecular-weight heparin (LMWH) that has 
      previously been shown to reduce the incidence of ischemic events in patients with 
      unstable angina or non-Q-wave MI. The principal aims of the TETAMI study are to 
      investigate the efficacy and safety of treatment with enoxaparin or tirofiban (a 
      glycoprotein IIb/IIIa receptor antagonist) alone or in combination for 2 to 8 
      days in patients with AMI who are not eligible for early reperfusion therapy. In 
      this 2 by 2 factorial design study approximately 900 patients will be randomly 
      assigned, in a blinded manner, to one of four treatments: enoxaparin alone, 
      enoxaparin plus tirofiban, unfractionated heparin (UFH), or UFH plus tirofiban, 
      with appropriate matched placebos. The primary end point is the composite of 
      death, recurrent AMI, and recurrent angina, analyzed at 30 days after AMI. The 
      design and methods of the TETAMI study are described in this article.
FAU - Cohen, M
AU  - Cohen M
AD  - Hahnemann University Hospital, Philadelphia, Pennsylvania 19102-1192, USA. 
      marc.cohen@tenethealth.com
FAU - Maritz, F
AU  - Maritz F
FAU - Gensini, G F
AU  - Gensini GF
FAU - Danchin, N
AU  - Danchin N
FAU - Timerman, A
AU  - Timerman A
FAU - Huber, K
AU  - Huber K
FAU - Gurfinkel, E P
AU  - Gurfinkel EP
FAU - White, H
AU  - White H
FAU - Fox, K A
AU  - Fox KA
FAU - Vittori, L
AU  - Vittori L
FAU - Le-Louer, V
AU  - Le-Louer V
FAU - Bigonzi, F
AU  - Bigonzi F
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Enoxaparin)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Placebos)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 42HK56048U (Tyrosine)
RN  - 9005-49-6 (Heparin)
RN  - GGX234SI5H (Tirofiban)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Clinical Protocols
MH  - Drug Therapy, Combination
MH  - Enoxaparin/*administration & dosage/standards/toxicity
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage/standards/toxicity
MH  - Heparin/*administration & dosage/standards/toxicity
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*drug therapy
MH  - Placebos
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - Recurrence
MH  - Survival Rate
MH  - Tirofiban
MH  - Tyrosine/*administration & dosage/*analogs & derivatives/standards/toxicity
EDAT- 2000/12/21 11:00
MHDA- 2001/03/27 10:01
CRDT- 2000/12/21 11:00
PHST- 2000/12/21 11:00 [pubmed]
PHST- 2001/03/27 10:01 [medline]
PHST- 2000/12/21 11:00 [entrez]
AID - 10.1023/a:1026543107533 [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2000 Dec;10(3):241-6. doi: 10.1023/a:1026543107533.